-+ 0.00%
-+ 0.00%
-+ 0.00%

Kalaris Therapeutics To Present Clinical Data From Phase 1 Study Of TH103 At 49th Annual Meeting Of Macula Society

Benzinga·01/28/2026 21:23:05
Listen to the news

Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of TH103 will be presented at the 49th Annual Meeting of the Macula Society, taking place February 25-28 in San Diego, California.

TH103 is a novel investigational therapy engineered by VEGF scientific pioneer Dr. Napoleone Ferrara to achieve enhanced VEGF inhibition and increased intraocular retention. The presentation will include safety, tolerability, pharmacokinetics and early efficacy outcomes following intravitreal administration of TH103 in patients with treatment-naive neovascular age-related macular degeneration. The data will be presented during a scientific session attended by leading retinal specialists and clinical investigators.